Sep 16, 2025 • Benzinga
SOMEWHAT-BULLISH
Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer
CHICAGO, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing transformative therapies for patients with rare and life-threatening diseases, today announced the appointment of Dr. Shaad Abedin as Chief Medical Officer.
Sep 10, 2025 • GlobeNewswire
NEUTRAL
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025
Oslo, Norway, 10 September 2025 - Zelluna ( OSE: ZLNA ) , a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer ( TCR-NK ) cells for the treatment of cancer, announces an Investor Science and Strategy Forum to be held in Oslo on Wednesday 17 September 2025 at ...
Aug 08, 2025 • Zacks Commentary
NEUTRAL
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Aug 08, 2025 • Zacks Commentary
NEUTRAL
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Aug 08, 2025 • Zacks Commentary
NEUTRAL
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Aug 08, 2025 • Zacks Commentary
NEUTRAL
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.